This video is a recording of Prostate Cancer Foundation Canada's 2024 Prostate Cancer Awareness Month Active Surveillance Support Group meeting held over Zoom. Dr. Ale Berlin is a staff clinician-scientist radiation oncologist at the Princess Margaret (PM) Cancer Center. He completed his training in Chile, Israel, and Canada. His clinical practice focuses on the discovery and clinical evaluation of novel therapeutics capitalizing on genomic characterization genitourinary malignancies, and advanced molecular and MR imaging. Dr. Berlin is a PI of the NRG GU010 study investigating the use of clinicogenomic risk stratification for treatment individualization in men with localized prostate cancer. Dr. Berlin also leads a clinical initiative quantifying the human and machine performance during the clinical deployment of an in-house developed AI radiotherapy planning method for prostate cancer. Dr. Alejandro Berlin speaks here on the impact of Gleason 6 being labelled as 'cancer' on treatment decision-making. For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's Coast to Coast Support Group meeting held over Zoom. Dr. Sofie Tolmeijer and Dr. Edmond Kwan from the Vancouver Prostate Centre discuss how tumour DNA testing and germline (genes inherited from one’s parents) testing will play an increasingly important role in selecting patients for new precision therapies. --- For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's November 2023 Coast to Coast Support Group meeting held over Zoom. Dr. Shamini Selvarajah is a clinical laboratory geneticist and Assistant Professor in the Department of Laboratory Medicine & Pathobiology - Cytogenetics at the University of Toronto. She holds a PhD, FACMGG, and FCCMG. Dr. Selvarajah is speaking here on '2023 Update on Genetic Testing Recommendations for Prostate Cancer Patients.' For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's January 2024 Coast to Coast Support Group meeting held over Zoom. Dr. Leong is an Associate Professor in the Department of Medicine at McMaster University. He is the Director of the McMaster University and Hamilton Health Sciences Cardio-Oncology Program. Dr. Leong completed his cardiology training, Doctor of Philosophy, Master of Public Health, and Master of Biostatistics degrees at the University of Adelaide, Australia. He completed a fellowship in cardiovascular imaging at the Leiden University Medical Centre in the Netherlands before re-locating to Canada. Dr. Leong is speaking here on Cardiovascular Health and Prostate Cancer. For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's March 2024 Coast to Coast Support Group meeting held over Zoom. Dr. Jack Barkin, the founding partner and medical director of Can-Am HIFU who performed the first Canadian HIFU (High-Intensity Focused Ultrasound) treatment in 2006, is speaking to us about this 'most effective, minimally invasive' localized prostate cancer treatment. He has authored over 100 papers on different aspects of urology in medical and urologic journals, worked on over 250 clinical trials, served as a medical advisory board member for many organizations, and speaks in countries around the world. For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's April 2024 Coast to Coast Support Group meeting held over Zoom. Danielle Ralic is the founder and CEO of Ancora.ai, a health tech company that connects cancer patients & their care teams to clinical trials through an AI-powered platform. She studied Finance and Information Systems with a specialty in Healthcare Information Technology at Boston College. She has over 15 years of experience implementing technology solutions in healthcare first with Deloitte in Boston working with hospitals and the public health department, and then at ZS Associates in Los Angeles and Zurich to deliver business intelligence solutions to Top10 Pharma. She is also an accomplished panelist and speaker sharing insights on advanced analytics applications in healthcare. Danielle is speaking here on Why We Should Care About Clinical Trials (And How to Stay in the Loop). For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of Prostate Cancer Foundation Canada's April 2024 Advanced Prostate Cancer Support Group meeting held over Zoom. Esteban Regalado is a nurse, and a former trauma RN specialist. Currently, he is the Director of Physician Education and Engagement for Telix Pharmaceuticals. He is a member of the Medical Science Liaison Society and the Society of Nuclear Medicine Molecular Imaging. Esteban Regalado is speaking here on on Advanced Prostate Cancer - Diagnostics and Treatments. For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), a nonprofit proudly providing leadership and resources in prostate cancer support, awareness, and research since 1997, please visit: prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.

This video is a recording of the Surrey Prostate Cancer Support Group's meeting in June 2022 featuring Alex Rolland and Michelle Morand of Cancer Treatment Options and Management (CTOAM). The organization is a team of researchers and educators with diverse backgrounds in cell biology, biochemistry, immunology, oncology, and clinical cancer. They committed to ensuring that the patients are aware of and have access to the most effective treatment available for their cancer, maximize the success of the treatment and limit side effects as much as possible. CTOAM will work and communicate with your urologist or oncologist to achieve the best results in your journey with cancer. For more information about Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC) and the support it provides to prostate cancer patients and their loved ones across Canada, please visit prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.